RT Journal Article
SR Electronic
T1 Management of Challenging Radioiodine Treatment Protocols: A Case Series and Review of the Literature
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 180
OP 185
DO 10.2967/jnmt.120.255307
VO 49
IS 2
A1 Waller, Joseph
A1 Lawhn-Heath, Courtney A.
A1 Edmonds, Cathleen
A1 Wendorf, Chloee
A1 Holmes, Brandon
A1 White, Michael
A1 Pampaloni, Miguel Hernandez
A1 Liu, Chienying
A1 Flavell, Robert R.
YR 2021
UL http://tech.snmjournals.org/content/49/2/180.abstract
AB Radioactive iodine (RAI) therapy with 131I is the standard of care for treatment in many patients with differentiated thyroid cancer. Because 131I is typically administered as a pill, and much of its radioactivity is excreted via the urine, there can be challenges in patients who cannot swallow pills, absorb iodine via the gastrointestinal tract, or eliminate RAI via the urine (i.e., dialysis patients and patients with renal failure). In this article, we present 3 cases in which the standard 131I treatment protocol for thyroid cancer could not be used because of these challenges, and we discuss the strategies used to overcome them. Provider collaboration and treatment customization are critical in overcoming patient-specific challenges.